ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2171 • ACR Convergence 2023

    Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?

    Yoshinobu Koyama1, Yoshiharu Sato2, Moe Tokunaga(Sakamoto)3 and Yu Nakai3, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan, 3Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan

    Background/Purpose: To date, there are no head-to-head clinical trials directly comparing the effects between IL-6i and JAKi on bone destruction in RA. In recent years,…
  • Abstract Number: 2451 • ACR Convergence 2023

    TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank

    Karen Costenbader1, Zhi Yu2, Emily G. Oakes3, Michelle Robinette4, Mridul Agarwal5, Buu Truong6, Md Mesbah Uddin6, Alexander Bick7, Abhishek Niroula6, Daniel Solomon3 and Pradeep Natarajan8, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Broad Institute; Massachusetts General Hospital, Cambridge, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital; Dana-Farber Cancer Institute, Boston, MA, 5Dana-Farber Cancer Institute, Boston, MA, 6Broad Institute, Cambridge, MA, 7Broad Institute; Vanderbilt University Medical Center, Nashville, TN, 8Broad Institute; Massachusetts General Hospital, Boston, MA

    Background/Purpose: Clonal hematopoiesis (CH), the clonal expansion of somatically mutated blood cells in people without hematologic malignancy, is found in ~10% of people age ≥…
  • Abstract Number: 2541 • ACR Convergence 2023

    Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity

    Joshua Baker1, James O'Dell2, Bryant England2, Jon Giles3, Jefferey Newcomb4, Michael George1, Geoffrey Thiele2, Larry Moreland5, S. Louis Bridges6, Jeffrey R Curtis7 and Ted R Mikuls8, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Columbia University, New York, NY, 4University of Nebraska, Omaha, NE, 5University of Colorado, Denver, CO, 6Hospital for Special Surgery, New York, NY, 7Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…
  • Abstract Number: 0025 • ACR Convergence 2023

    Relationship Between Genetic Variants in Cannabinoid Receptor 2 and Self-Reported Effectiveness of Cannabis for Pain Management in Rheumatoid Arthritis

    Kristin Wipfler1, Joanna Zeiger2, Adam Cornish1 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2Canna Research Foundation, Boulder, CO, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Cannabinoid receptor 2 (CB2) is a member of the cannabinoid receptor family and is encoded by the CNR2 gene. CB2 receptors are found primarily…
  • Abstract Number: 0088 • ACR Convergence 2023

    SLAMF4 Orchestrates the Pathological Cytotoxic Response of CD4+ T Cells in Rheumatoid Arthritis

    Megane Lacaud1, Houda-Ghozlane Bouzidi1, Magali breckler1, Delphine Lemeiter2, Luca Semerano3, Marie-Christophe Boissier3, Natacha Bessis4 and Jerome Biton2, 1Inserm UMR 1225, Université Sorbonne Paris Nord, Bobigny, France, 2Inserm UMR 1125, Université Sorbonne Paris Nord, Bobigny, France, 3Inserm UMR 1125, Université Sorbonne Paris Nord; Assistance Publique-Hôpitaux de Paris, Rheumatology department, Avicenne Hospital, Bobigny, France, 4Inserm UMR 1125, Université Sorbonne Paris Nord, Bobigny, France

    Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Recent studies, aided by a…
  • Abstract Number: 0223 • ACR Convergence 2023

    Severity and Risk Factors of Hospitalization of Omicron in Patients with Rheumatoid Arthritis

    Yan Wang1, mengyao zhang2, Sitian Zang1, liang luo3, Chun Li1, Jing He1 and zhanguo li2, 1Peking University People’s Hospital, Beijing, China, 2Peking University People's Hospital, Beijing, China, 3Department of Chinese Medicine, the People's Hospital of Yubei District of Chongqing City, Chongqing, China; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China

    Background/Purpose: There is still lack of data on the prognosis of patients with RA who have been infected with SARS-Cov-2 Omicron variant, a new strain…
  • Abstract Number: 0387 • ACR Convergence 2023

    The Association Between Inflammation, High-Sensitivity Cardiac Troponin T, and Cardiovascular Events in Rheumatoid Arthritis

    Brittany Weber1, Dana Weisenfeld1, Mary Jeffway1, Jonathan Coblyn1, Michael Weinblatt2, Nancy Shadick3, Marcelo DiCarli1 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Waban, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a 1.5x excess risk of cardiovascular (CV) disease compared to the general population, attributed to chronic inflammation. In…
  • Abstract Number: 0403 • ACR Convergence 2023

    Disease Activity Is Associated with Frailty in Veterans with Rheumatoid Arthritis

    Courtney Loecker1, Bryant England2, Punyasha Roul2, Namrata Singh3, Kaleb Michaud2, Lani Zimmerman4, Myra Schmaderer4, Grant Cannon5, Ted R Mikuls6, Gary Kunkel7, Ariela Orkaby8, Joshua Baker9 and K Wysham10, 1University of Nebraska Medical Center;VA Nebraska-Western Iowa Health Care System, Lincoln, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Washington, Bellevue, WA, 4University of Nebraska Medical Center, Lincoln, NE, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 7VA Salt Lake City & University of Utah, Salt Lake City, UT, 8Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, 9University of Pennsylvania, Philadelphia, PA, 10VA Puget Sound/University of Washington, Seattle, WA

    Background/Purpose: Frailty, defined as an increased vulnerability to stressors and adverse health outcomes, is an emerging concept in RA. Active RA disease gives rise to…
  • Abstract Number: 0420 • ACR Convergence 2023

    Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers

    Gregory McDermott1, Keigo Hayashi1, Matthew Moll1, Michael Cho1, Kazuki Yoshida1, Tracy J. Doyle1, Gregory Kinney2, Paul Dellaripa3, Zachary Wallace4, Elizabeth Regan5, Gary Hunninghake1, Edwin Silverman1, Samuel Ash1, Raul San Jose Estepar1, George Washko1 and Jeffrey Sparks6, 1Brigham and Women's Hospital, Boston, MA, 2University of Colorado Denver, Denver, CO, 3Brigham and Women's Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5National Jewish Health, Denver, CO, 6Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Quantitative computed tomography (QCT) methods have been developed to automatically quantify parenchymal lung features on chest CT imaging. There have been limited investigations of…
  • Abstract Number: 0437 • ACR Convergence 2023

    Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis

    Xavier Sendaydiego1, Laura Gold2, K Wysham3, Jean liew4, Maureen Dubreuil5, James Andrews1, Pankti Reid6, David Liew7, Radjiv Goulabchand8, Abha Singh9, Grant Hughes1, Mathilde Pioro1, Jeffrey Sparks10, Jeffrey Jarvik2, Siddharth Singh9 and Namrata Singh11, 1University of Washington, Seattle, WA, 2Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, 3VA Puget Sound/University of Washington, Seattle, WA, 4Boston University, Boston, MA, 5Department of Rheumatology, Boston University School of Medicine, Milton, MA, 6University of Chicago Medical Center, Chicago, IL, 7Austin Health, Heidelberg, Australia, 8St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, 9University of California San Diego, San Diego, CA, 10Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 11University of Washington, Bellevue, WA

    Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
  • Abstract Number: 0454 • ACR Convergence 2023

    Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices

    Theodore Pincus1, Nicholas Rodwell2 and Rahel Hunter1, 1Rush University Medical Center, Chicago, IL, 2University of New South Wales, Sydney, Australia

    Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…
  • Abstract Number: 0732 • ACR Convergence 2023

    Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?

    Roba Ghossan1, Omar AL TABAA2, Alice Combier3, Alexia STEELANDT3, Marion THOMAS3, Olivier Fogel3, Corinne MICELI4, Anna Molto3 and Jérôme Avouac5, 1COCHIN HOSPITAL, Paris, France, 2APHP / Cochin Hospital, Paris, France, 3HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 4Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 5Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France

    Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…
  • Abstract Number: 0796 • ACR Convergence 2023

    Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis

    Anders Nguyen1, Agnieszka Lastowska1, Miriam Bollmann1, Symeon Kourmoulakis1, Charlotte E. van der Plas1, Anna-Karin Hultgård Ekwall2, Dietmar M. Zaiss3, Gary S Firestein4 and Mattias N.D Svensson5, 1Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, 3Faculty of Medicine, Department of Immune Medicine, University of Regensburg, Regensburg, Germany, Regensburg, Germany, 4Department of Medicine, University of California San Diego, La Jolla, CA, 5University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Immune-cell mediated activation of joint-lining fibroblast-like synoviocytes (FLS) play a key role in joint inflammation and destruction during Rheumatoid arthritis (RA). Thus, identifying factors…
  • Abstract Number: 0860 • ACR Convergence 2023

    Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation

    Chandramohan Natarajan1, Julia Lucchino1, David Chenoff2 and Yaakov Levine1, 1SetPoint Medical, Valencia, CA, 2SetPoint Medical, Sausalito, CA

    Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…
  • Abstract Number: 0991 • ACR Convergence 2023

    Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database

    Dongxing Xie1, Qiao Jiang2, Yuqing Wang2, Huizhong Long2, Hu Chen3, Jie Wei4, Xiaoxiao Li5, Haibo Wang6, Chao Zeng7 and Guanghua Lei7, 1Xiangya Hospital, Central South University, Changsha, China, 2Xiangya Hospital, Changsha, China, 3Tibet Autonomous Region People’s Hospital, Lhasa, China, 4Health Management Center, Xiangya Hospital Central South University, Changsha, China, 5Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, 6China Standard Medical Information Research Center, Shenzhen, China, 7Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China

    Background/Purpose: For end-stage inflammatory arthritis (IA) including rheumatoid arthritis (RA) and spondyloarthritis (SpA), joint arthroplasty is the only treatment option, but is considered to be…
  • « Previous Page
  • 1
  • …
  • 79
  • 80
  • 81
  • 82
  • 83
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology